tert-butyl (2S,4S)-4-(4-(2-aminothiazolo[5,4-b]pyridin-5-yl)-1H-1,2,3-triazol-1-yl)-2-((4-bromophenyl)carbamoyl)pyrrolidine-1-carboxylate

ID: ALA5196374

Chembl Id: CHEMBL5196374

PubChem CID: 168284372

Max Phase: Preclinical

Molecular Formula: C24H25BrN8O3S

Molecular Weight: 585.49

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)(C)OC(=O)N1C[C@@H](n2cc(-c3ccc4nc(N)sc4n3)nn2)C[C@H]1C(=O)Nc1ccc(Br)cc1

Standard InChI:  InChI=1S/C24H25BrN8O3S/c1-24(2,3)36-23(35)32-11-15(10-19(32)20(34)27-14-6-4-13(25)5-7-14)33-12-18(30-31-33)16-8-9-17-21(28-16)37-22(26)29-17/h4-9,12,15,19H,10-11H2,1-3H3,(H2,26,29)(H,27,34)/t15-,19-/m0/s1

Standard InChI Key:  FVYMRGNWPDZIDO-KXBFYZLASA-N

Alternative Forms

  1. Parent:

    ALA5196374

    ---

Associated Targets(Human)

ABL1 Tclin Bcr/Abl fusion protein (1667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562/Adr (229 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 585.49Molecular Weight (Monoisotopic): 584.0954AlogP: 4.48#Rotatable Bonds: 4
Polar Surface Area: 141.15Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.22CX Basic pKa: 0.21CX LogP: 4.34CX LogD: 4.34
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.36Np Likeness Score: -1.72

References

1. Pan X, Liu N, Liu Y, Zhang Q, Wang K, Liu X, Zhang J..  (2022)  Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.,  238  [PMID:35561654] [10.1016/j.ejmech.2022.114425]

Source